JP2023540733A - アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用 - Google Patents

アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用 Download PDF

Info

Publication number
JP2023540733A
JP2023540733A JP2023514910A JP2023514910A JP2023540733A JP 2023540733 A JP2023540733 A JP 2023540733A JP 2023514910 A JP2023514910 A JP 2023514910A JP 2023514910 A JP2023514910 A JP 2023514910A JP 2023540733 A JP2023540733 A JP 2023540733A
Authority
JP
Japan
Prior art keywords
compound
disease
compound according
pharmaceutical composition
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023514910A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022051582A5 (https=
JP2023540733A5 (https=
Inventor
マーク ジー． ボック
デイビッド ハリソン
ジェーン イー． スカンロン
Original Assignee
ノッドセラ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノッドセラ リミテッド filed Critical ノッドセラ リミテッド
Publication of JP2023540733A publication Critical patent/JP2023540733A/ja
Publication of JPWO2022051582A5 publication Critical patent/JPWO2022051582A5/ja
Publication of JP2023540733A5 publication Critical patent/JP2023540733A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023514910A 2020-09-04 2021-09-03 アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用 Pending JP2023540733A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063074521P 2020-09-04 2020-09-04
US63/074,521 2020-09-04
PCT/US2021/049001 WO2022051582A1 (en) 2020-09-04 2021-09-03 Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof

Publications (3)

Publication Number Publication Date
JP2023540733A true JP2023540733A (ja) 2023-09-26
JPWO2022051582A5 JPWO2022051582A5 (https=) 2024-09-09
JP2023540733A5 JP2023540733A5 (https=) 2024-09-09

Family

ID=77951864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514910A Pending JP2023540733A (ja) 2020-09-04 2021-09-03 アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用

Country Status (12)

Country Link
US (1) US20240043410A1 (https=)
EP (1) EP4208459A1 (https=)
JP (1) JP2023540733A (https=)
KR (1) KR20230061505A (https=)
CN (1) CN116783184A (https=)
AR (1) AR123435A1 (https=)
AU (1) AU2021336518A1 (https=)
BR (1) BR112023003792A2 (https=)
CA (1) CA3191410A1 (https=)
IL (1) IL301055A (https=)
MX (1) MX2023002686A (https=)
WO (1) WO2022051582A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
PL3983387T3 (pl) 2019-06-12 2024-08-19 NodThera Limited Pochodne sulfonylomocznika i ich zastosowania
WO2025104268A1 (en) 2023-11-17 2025-05-22 NodThera Limited Forms of urea derivatives and related uses
WO2025104244A1 (en) * 2023-11-17 2025-05-22 NodThera Limited Methods of preparing urea derivatives
WO2025153532A1 (en) * 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121691A1 (en) * 2017-12-18 2019-06-27 NodThera Limited Sulphonyl urea derivatives as nlrp3 inflammasome modulators
WO2020035464A1 (en) * 2018-08-15 2020-02-20 Inflazome Limited Novel sulfonamideurea compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
PT1270565E (pt) 1997-01-29 2004-09-30 Pfizer Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia
SI3259253T1 (sl) * 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
ES2988798T3 (es) 2017-07-24 2024-11-21 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121691A1 (en) * 2017-12-18 2019-06-27 NodThera Limited Sulphonyl urea derivatives as nlrp3 inflammasome modulators
WO2020035464A1 (en) * 2018-08-15 2020-02-20 Inflazome Limited Novel sulfonamideurea compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
""Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment", FRONTIERS IN IMMUNOLOGY, vol. 11, JPN6025030569, 19 May 2020 (2020-05-19), pages Adnan SHAH, ISSN: 0005650200 *
SANDRO AUGUSTO RIBEIRO ET AL.: ""The therapeutic potential of colchicine in the complications of COVID19. Could the immunometabolic", METABOLISM OPEN, vol. 7, JPN6025030570, September 2020 (2020-09-01), pages 100045, ISSN: 0005650201 *
TRACEY L. FREEMAN ET AL.: ""Targeting the NLRP3 Inflammasome in Severe COVID-19"", FRONTIERS IN IMMUNOLOGY, vol. 11, JPN6025030568, 23 June 2020 (2020-06-23), ISSN: 0005650199 *

Also Published As

Publication number Publication date
KR20230061505A (ko) 2023-05-08
WO2022051582A1 (en) 2022-03-10
MX2023002686A (es) 2023-04-03
IL301055A (en) 2023-05-01
AR123435A1 (es) 2022-11-30
EP4208459A1 (en) 2023-07-12
CA3191410A1 (en) 2022-03-10
CN116783184A (zh) 2023-09-19
US20240043410A1 (en) 2024-02-08
BR112023003792A2 (pt) 2023-03-28
AU2021336518A1 (en) 2023-03-23
TW202229265A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
JP7339959B2 (ja) Ｎｌｒｐ３インフラマソーム調節剤としてのスルホニル尿素誘導体
TWI810198B (zh) Nlrp3發炎體之選擇性抑制劑
JP2023540733A (ja) アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用
KR20210098960A (ko) Helios의 소분자 분해제 및 사용 방법
JP7661248B2 (ja) スルホニル尿素誘導体及びその使用
JP7682813B2 (ja) スルホニル尿素誘導体及びその使用
JP2022535955A (ja) スルホンアミド誘導体及びその使用
JP2022518526A (ja) カルバメート誘導体およびその使用
RU2858266C2 (ru) Производные сульфамоилмочевины, содержащие алкилоксациклоалкильную группу, и их применения
TWI916398B (zh) 含有烷基－氧雜環烷基部分之胺磺醯基脲衍生物及其用途
KR20240145992A (ko) 비사이클릭 프탈라진-1(2h)-온 유도체 및 관련 용도

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260420